New phase II trial of avelumab, a PD-L1 inhibitor, in recurrent respiratory papillomatosis
Electron micrograph of a cancer cell being attacked by T cells, part of a natural immune response.
Dr. Christian Hinrichs, Investigator and Lasker Clinical Research Scholar in the Experimental Transplantation and Immunology Branch, is leading a trial of avelumab in patients with recurrent respiratory papillomatosis (RRP). This rare disease is caused by human papillomavirus (HPV) and can cause tumors to grow in the throat, vocal cords, and lungs. These wart-like tumors can reappear even after surgery to remove them. Avelumab interferes with PD-L1, a protein on cells that stops the immune system from attacking viruses such as HPV. Researchers want to study avelumab on RRP without causing harmful side effects. Adults 18 and older may contact Erin Ferraro, RN, at 301-594-0687 to discuss eligibility. View Protocol Description.Summary Posted: 08/2016